60.73
price down icon3.66%   -2.31
after-market After Hours: 61.51 0.78 +1.28%
loading
Metsera Inc stock is traded at $60.73, with a volume of 4.90M. It is down -3.66% in the last 24 hours and up +17.01% over the past month. Metsera Inc is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient-stimulated hormone (NuSH) analog peptides to treat obesity, overweight, and related conditions. The Company has developed and is implementing proprietary methods and platform technologies to advance a broad, scalable, and combinable portfolio of injectable and oral NuSH analog peptides with the potential to address not only the limitations of approved therapies but also many of the anticipated limitations of next-generation therapies in development. The Company uses its proprietary MINT peptide library of NuSH analog peptides alongside its Half-life Augmentation by Lipid Optimization half-life extending platform.
See More
Previous Close:
$63.04
Open:
$61.1
24h Volume:
4.90M
Relative Volume:
2.20
Market Cap:
$6.38B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+16.45%
1M Performance:
+17.01%
6M Performance:
+136.76%
1Y Performance:
+0.00%
1-Day Range:
Value
$60.37
$61.85
1-Week Range:
Value
$51.84
$66.10
52-Week Range:
Value
$12.30
$66.10

Metsera Inc Stock (MTSR) Company Profile

Name
Name
Metsera Inc
Name
Phone
(212) 784-6595
Name
Address
3 WORLD TRADE CENTER, NEW YORK
Name
Employee
109
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
MTSR's Discussions on Twitter

Compare MTSR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
MTSR
Metsera Inc
60.73 6.63B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
426.00 109.11B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.25 68.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
434.07 60.25B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
826.28 50.39B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
186.23 40.44B 447.02M -1.18B -868.57M -6.1812

Metsera Inc Stock (MTSR) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-30-25 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-25 Initiated Leerink Partners Outperform
Jun-20-25 Initiated Wells Fargo Overweight
Feb-25-25 Initiated BofA Securities Buy
Feb-25-25 Initiated Evercore ISI Outperform
Feb-25-25 Initiated Guggenheim Buy
View All

Metsera Inc Stock (MTSR) Latest News

pulisher
Nov 03, 2025

Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView

Nov 03, 2025
pulisher
Nov 03, 2025

Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit - Reuters

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer’s And Novo’s Competing Bids For Metsera Devolve Into Lawsuits, Name Calling - Citeline News & Insights

Nov 03, 2025
pulisher
Nov 03, 2025

ACQUISITIONS & MERGERS NEWS: Pfizer sues Metsera and Novo Nordisk to halt their proposed merger - VitalLaw.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer, Novo's Metsera war could redraw the map for obesity treatments - Axios

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Hits Novo Nordisk In Fed. Court Over $9B Metsera Deal - Law360

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera, Inc. Responds to Pfizer’s Litigation Claims - MSN

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo - Investor's Business Daily

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War - Bloomberg.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News

Nov 03, 2025
pulisher
Nov 03, 2025

Market Voices: Pfizer-Novo Nordisk legal battle; Trump on Zhao pardon - MSN

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Files Lawsuits Against Metsera and Novo Nordisk - Pharmaceutical Executive

Nov 03, 2025
pulisher
Nov 03, 2025

Coinbase Said Web3 - Bloomberg.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer sues to block Novo Nordisk bid for obesity drug maker Metsera - The Business Journals

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files US court challenge to Novo's bid for Metsera - MLex

Nov 03, 2025
pulisher
Nov 03, 2025

FinCEN Offers Relief to Banks on ‘Overwhelming’ SARs Filings - PYMNTS.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files second lawsuit against Metsera, Novo Nordisk - whbl.com

Nov 03, 2025
pulisher
Nov 03, 2025

Novo Nordisk’s Attempt to Buy Metsera is Anticompetitive, Says Pfizer in Second Lawsuit - TipRanks

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute - MSN

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera rejects Pfizer litigation as attempt to lower acquisition price - Investing.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer sues Novo, Metsera for second time in brewing deal war - Crain's New York Business

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera issues statement regarding Pfizer litigation and proposed acquisition By Investing.com - Investing.com UK

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera issues statement regarding Pfizer litigation and proposed acquisition - Investing.com

Nov 03, 2025
pulisher
Nov 03, 2025

Novo Nordisk says Metsera bid won’t raise antitrust issues By Reuters - Investing.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute (PFE:NYSE) - Seeking Alpha

Nov 03, 2025
pulisher
Nov 03, 2025

Novo Nordisk says Metsera bid won't raise antitrust issues - Reuters

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera - The Wall Street Journal

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera - Barron's

Nov 03, 2025
pulisher
Nov 03, 2025

Novo Nordisk spokesperson says Pfizer's claims against co's Metsera offer is "without merit" - MarketScreener

Nov 03, 2025
pulisher
Nov 03, 2025

Another Pfizer lawsuit to stop Novo bid for Metsera - The Pharma Letter

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech - CNBC

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk - Nasdaq

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera Responds to Pfizer's Legal Action Amid Bid Interest from Novo Nordisk (NVO) - GuruFocus

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera to address Pfizer's litigation in court - MarketScreener

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera Issues Statement in Response to Litigation - Yahoo Finance

Nov 03, 2025
pulisher
Nov 03, 2025

UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid - BioSpace

Nov 03, 2025
pulisher
Nov 03, 2025

How to build a custom watchlist for Metsera Inc.Market Growth Summary & Weekly Setup with High ROI Potential - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Metsera Inc. stock entering bullish territory2025 Dividend Review & Community Supported Trade Ideas - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files two lawsuits to stop Novo's $9B buyout of Metsera - BioWorld MedTech

Nov 03, 2025
pulisher
Nov 03, 2025

Is Metsera Inc. stock a safe investment in uncertain marketsTrade Entry Summary & Reliable Trade Execution Plans - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files another lawsuit: Accuses Metsera owners of conspiring with Novo Nordisk - medwatch.com

Nov 03, 2025
pulisher
Nov 03, 2025

Metsera falls after Pfizer files a second lawsuit against co and Novo - TradingView

Nov 03, 2025
pulisher
Nov 03, 2025

How currency fluctuations impact Metsera Inc. stockJuly 2025 Summary & Proven Capital Preservation Tips - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid - GuruFocus

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Benzinga

Nov 03, 2025
pulisher
Nov 03, 2025

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit - MSN

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid - Financial Times

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer files second lawsuit against Novo Nordisk, Metsera in battle over obesity startup - statnews.com

Nov 03, 2025
pulisher
Nov 03, 2025

Pfizer sues Novo Nordisk and Metsera once againbid considered to restrict competition - MarketScreener

Nov 03, 2025
pulisher
Nov 03, 2025

Why Metsera Inc. stock appeals to analystsEntry Point & Advanced Technical Signal Analysis - newser.com

Nov 03, 2025

Metsera Inc Stock (MTSR) Financials Data

There is no financial data for Metsera Inc (MTSR). Check out other stocks for more information.

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$37.30
price down icon 0.64%
$28.71
price up icon 0.35%
$101.57
price up icon 8.65%
$103.95
price up icon 0.04%
biotechnology ONC
$311.86
price up icon 0.44%
$186.23
price down icon 1.78%
Cap:     |  Volume (24h):